BNP Paribas reiterated their outperform rating on shares of Shire PLC (LON:SHP) in a research note released on Friday. The brokerage currently has a GBX 5,900 ($77.01) price objective on the biopharmaceutical company’s stock.
A number of other brokerages have also weighed in on SHP. HSBC lowered Shire PLC to a hold rating and cut their price objective for the stock from GBX 5,400 ($70.49) to GBX 5,250 ($68.53) in a research report on Monday, September 26th. JPMorgan Chase & Co. reiterated an overweight rating on shares of Shire PLC in a research report on Friday, September 23rd. Shore Capital reiterated a buy rating on shares of Shire PLC in a research report on Wednesday, September 28th. Citigroup Inc. reiterated a buy rating on shares of Shire PLC in a research report on Tuesday, September 27th. Finally, Berenberg Bank reiterated a buy rating and issued a GBX 5,800 ($75.71) price objective on shares of Shire PLC in a research report on Tuesday, September 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Shire PLC presently has an average rating of Buy and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5091.00 on Friday. The company has a 50-day moving average price of GBX 4,982.30 and a 200-day moving average price of GBX 4,542.61. The stock’s market capitalization is GBX 34.76 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other news, insider Dominic Blakemore acquired 133 shares of the business’s stock in a transaction that occurred on Friday, September 30th. The stock was bought at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.